ALN-VSP is a systemically delivered RNAi therapeutic which includes two siRNAs intended to target two genes critical for the growth and development of cancer cells: vascular endothelial growth factor (VEGF) and kinesin spindle protein (KSP), also known as eglin 5 (Eg5).
In the trial, the patients were treated at doses ranging from 0.1 to 1.5 mg/kg.
Alnylam Clinical Research senior director Jared Gollob said the results of ALN-VSP Phase I trial demonstrated safety and tolerability of multiple doses of ALN-VSP in addition to evidence for anti-tumor activity and proof of RNAi mechanism from tissue biopsy samples.